Merck (NYSE: MRK), known as MSD outside of the United States and Canada, has announced the completion of the acquisition of Eyebiotech Limited (EyeBio). EyeBio is now a wholly-owned subsidiary of Merck. EyeBio’s lead candidate, Restoret™ (EYE103), is an investigational, potentially first-in-class tetravalent, tri-specific antibody that acts as an agonist of the Wingless-related integration site (Wnt) signaling pathway.
Read the full article: Merck Completes Acquisition of EyeBio //
Source: https://www.businesswire.com/news/home/20240712972802/en/Merck-Completes-Acquisition-of-EyeBio